article

Kick-starting the immune response – the shifting landscape of immuno-oncology

The landscape of cancer treatment has changed dramatically in the last seven years, beginning with the approval of Ipilmumab in 2011, the first immunotherapy drug. Efforts to unsheathe the tumour cells of their protective microenvironment and expose them to an active immune response have delivered several monoclonal antibodies (mAbs) that are now in the clinic. Eleven new immunotherapies have since been approved and are fast becoming a standard route of treatment for many patients.











To read this article in full, please complete the form below. By clicking submit you confirm that you accept our terms and conditions and privacy policy.


*

*

*

*

*

*

*

*

This content is provided to you for free thanks to the kind support of our sponsor: Cisbio

 

 

Send this to a friend